Aldeyra Therapeutics Faces Further Reproxalap FDA Delay, PDUFA Extended to March 2026
ALDX has more than doubled off its 52-week low of $1.14.
Summary
Aldeyra Therapeutics' lead dry eye drug, reproxalap, faces further FDA delays, pushing the PDUFA date to March 2026 and impacting a key collaboration option with AbbVie.
Key Events · Product Development and Regulatory · ALDX
-
Reproxalap FDA Approval Delayed Again
The FDA issued a second Complete Response Letter (CRL) for reproxalap in April 2025, requesting more efficacy data for ocular symptoms. A subsequent resubmission in June 2025 led to the FDA requesting the field trial submission in December 2025, extending the PDUFA target action date to March 16, 2026.
-
AbbVie Collaboration Option Contingent on Approval
AbbVie's exclusive option to collaborate on reproxalap, which includes a potential $100 million upfront payment, remains unexercised as of February 27, 2026, directly impacted by the ongoing FDA approval delays.
-
Improved Financial Performance Amidst Pipeline Rationalization
Net loss decreased to $33.8 million in 2025 from $55.9 million in 2024, partly due to a significant reduction in R&D expenses from deprioritizing programs like ADX-629 and ADX-2191 for proliferative vitreoretinopathy.
-
Near-Term Liquidity and Debt Maturity
The company reports cash and cash equivalents of $70.0 million as of December 31, 2025, sufficient for at least 12 months, but faces a $15.0 million debt maturity in April 2026.
Analysis · ALDX · Life Sciences
Aldeyra Therapeutics' annual report highlights significant ongoing regulatory challenges for its lead dry eye disease candidate, reproxalap. The company received a second Complete Response Letter (CRL) from the FDA in April 2025, citing insufficient efficacy data for ocular symptoms. A subsequent resubmission led to the FDA requesting additional trial data in December 2025, extending the PDUFA target action date to March 16, 2026. This continued delay is critical as the exercise of a substantial collaboration option with AbbVie, including a potential $100 million upfront payment, is contingent on FDA approval. While the company reported a reduced net loss for 2025 and has sufficient cash for at least 12 months, the reproxalap setback creates significant uncertainty for its near-term financial and strategic outlook. Investors should monitor the upcoming PDUFA date closely, as the outcome will heavily influence the AbbVie partnership and the company's future capital needs.
At the time of this filing, ALDX was trading at $5.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $328.5M. The 52-week trading range was $1.14 to $7.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.